HCW Biologics Inc is trading 5.4% down at $1.04 today, giving back a portion of its recent rebound as the initial excitement over clinical trial data cools.
- The stock experienced a significant surge during after-hours trading on June 17 following the release of positive preliminary Phase 1 data for HCW9302 in alopecia areata.
- There are no new company-specific headlines today, June 18, suggesting the decline is driven by normal volatility and profit-taking rather than a reaction to new information.
- The pullback occurs despite major market indices trading broadly higher, highlighting a correction from the recent news-driven spike.